Q3 2021 Investor Relations Results

Participants Company overview Pharmaceuticals Financial performance Oncology Financial review Conclusion Appendix References Innovation: Pipeline overview Innovation: Clinical trials CRM IHD Neuroscience Ophthalmology Respiratory & Allergy Oncology: Solid Tumors Hematology Biosimilars Global Health Abbreviations PiqrayⓇ - PI3K-alpha inhibitor Study Indication Phase Patients Primary Outcome Measures Arms Intervention Target Patients NCT04208178 EPIK-B2 (CBYL719G12301) HER-2 positive breast cancer Phase 3 548 Progression-free survival (PFS) Alpelisib + trastuzumab + pertuzumab Trastuzumab + pertuzumab Patients with HER2-positive advanced breast cancer with a PIK3CA mutation Read-out Milesstone(s) 2025 Publication TBD NCT04251533 EPIK-B3 (CBYL719H12301) Triple negative breast cancer Phase 3 566 Progression-free Survival (PFS) for patients with PIK3CA mutant status Alpelisib 300 mg + nab-paclitaxel 100 mg/m² Placebo nab-paclitaxel 100 mg/m² Patients with advanced triple negative breast cancer with either Phosphoinositide-3- kinase Catalytic Subunit Alpha (PIK3CA) mutation or Phosphatase and Tensin Homolog Protein (PTEN) loss without PIK3CA mutation 2023 TBD 112 Investor Relations | Q3 2021 Results NOVARTIS | Reimagining Medicine

View entire presentation